[go: up one dir, main page]

MX2008002512A - Composiciones de farmaco que contienen matrices de hipromelosa con liberacion controlada. - Google Patents

Composiciones de farmaco que contienen matrices de hipromelosa con liberacion controlada.

Info

Publication number
MX2008002512A
MX2008002512A MX2008002512A MX2008002512A MX2008002512A MX 2008002512 A MX2008002512 A MX 2008002512A MX 2008002512 A MX2008002512 A MX 2008002512A MX 2008002512 A MX2008002512 A MX 2008002512A MX 2008002512 A MX2008002512 A MX 2008002512A
Authority
MX
Mexico
Prior art keywords
controlled release
compositions containing
drug compositions
containing controlled
matrices
Prior art date
Application number
MX2008002512A
Other languages
English (en)
Inventor
Ali Rajabi-Siahboomi
Kurt Alan Fegely
Kara Young
Pankaj Rege
Original Assignee
Bpsi Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bpsi Holdings Inc filed Critical Bpsi Holdings Inc
Publication of MX2008002512A publication Critical patent/MX2008002512A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta invencion esta dirigida a una formulacion con liberacion controlada para una forma de dosis oral que es formulada en una matriz hidrofilica expandible. La formulacion con liberacion controlada contiene una mezcla la hipromelosa y ftalato acetato de polivinilo y permite combinar ingredientes activos farmaceuticos entre si para ser liberados de una manera controlada.
MX2008002512A 2005-08-26 2006-08-25 Composiciones de farmaco que contienen matrices de hipromelosa con liberacion controlada. MX2008002512A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71172405P 2005-08-26 2005-08-26
PCT/US2006/033309 WO2007025182A2 (en) 2005-08-26 2006-08-25 Drug compositions containing controlled release hypromellose matrices

Publications (1)

Publication Number Publication Date
MX2008002512A true MX2008002512A (es) 2008-04-03

Family

ID=37772457

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008002512A MX2008002512A (es) 2005-08-26 2006-08-25 Composiciones de farmaco que contienen matrices de hipromelosa con liberacion controlada.

Country Status (13)

Country Link
US (1) US20070048377A1 (es)
EP (1) EP1926479A4 (es)
JP (1) JP2009506070A (es)
KR (1) KR20080047571A (es)
CN (1) CN101247790A (es)
AU (1) AU2006282900B2 (es)
BR (1) BRPI0615135A2 (es)
CA (1) CA2620108A1 (es)
IL (1) IL189631A0 (es)
MX (1) MX2008002512A (es)
RU (1) RU2414241C2 (es)
WO (1) WO2007025182A2 (es)
ZA (1) ZA200801478B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012068076A2 (en) * 2010-11-15 2012-05-24 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations containing soluble drugs
NL2009273A (en) 2011-08-31 2013-03-04 Asml Netherlands Bv Level sensor arrangement for lithographic apparatus, lithographic apparatus and device manufacturing method.
WO2013169523A1 (en) * 2012-05-07 2013-11-14 Bpsi Holdings, Llc. Solubility enhanced compositions
AU2014306759B2 (en) 2013-08-12 2018-04-26 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
JP5843986B2 (ja) * 2014-03-25 2016-01-13 アステラス製薬株式会社 粒状医薬組成物
DK3169315T3 (da) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
WO2016064873A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
RU2624857C1 (ru) * 2016-01-26 2017-07-07 федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургская государственная химико-фармацевтическая академия" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПХФА Минздрава России) Фармацевтическая композиция с противогрибковой активностью и способ ее получения
AR113882A1 (es) 2017-11-16 2020-06-24 Nippon Shinyaku Co Ltd Preparación de liberación controlada
WO2020157730A1 (en) 2019-02-03 2020-08-06 Patel Jayendrakumar Dasharathlal A controlled release pharmaceutical composition of selexipag or it's active metabolite

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL95423A (en) * 1989-09-21 1994-11-11 American Cyanamid Co Pulsatile once-a-day delivery systems for minocycline
US5733575A (en) * 1994-10-07 1998-03-31 Bpsi Holdings, Inc. Enteric film coating compositions, method of coating therewith, and coated forms
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US6726931B2 (en) * 2002-04-08 2004-04-27 Standard Chem. & Pharm. Co., Ltd. Process for preparing oral sustained-release formulation of felodipine
WO2004041244A2 (en) * 2002-10-30 2004-05-21 Pharmacia Corporation Oral extended release tablets and methods of making and using the same
ES2545454T3 (es) * 2002-12-10 2015-09-11 Nortec Development Associates, Inc. Método de preparación de formulaciones biológicamente activas
JP4614139B2 (ja) * 2003-08-12 2011-01-19 キョンドン ファーム カンパニー リミテッド 塩酸タムスロシン徐放性錠剤の製造方法、およびそれからなる塩酸タムスロシン徐放性錠剤
EP1675574A2 (en) * 2003-10-08 2006-07-05 Ranbaxy Laboratories, Ltd. Pharmaceutical compositions of paroxetine containing microcrystalline cellulose, prepared by wet granulation
CN1874767A (zh) * 2003-10-29 2006-12-06 惠氏公司 包含aplindore和其衍生物的缓释药物组合物

Also Published As

Publication number Publication date
CA2620108A1 (en) 2007-03-01
EP1926479A4 (en) 2013-01-09
WO2007025182A3 (en) 2007-09-07
EP1926479A2 (en) 2008-06-04
AU2006282900A1 (en) 2007-03-01
CN101247790A (zh) 2008-08-20
BRPI0615135A2 (pt) 2016-09-13
WO2007025182A2 (en) 2007-03-01
ZA200801478B (en) 2008-12-31
IL189631A0 (en) 2008-06-05
AU2006282900B2 (en) 2011-11-03
KR20080047571A (ko) 2008-05-29
RU2008111497A (ru) 2009-10-10
RU2414241C2 (ru) 2011-03-20
JP2009506070A (ja) 2009-02-12
US20070048377A1 (en) 2007-03-01

Similar Documents

Publication Publication Date Title
AP1954A (en) Controlled release compositions comprising nimesulide.
MX381895B (es) Formulaciones farmaceuticas de liberacion controlada de nitazoxanida.
NL2000281A1 (nl) Vaste farmaceutische samenstellingen die pregabaline bevatten.
WO2009063222A3 (en) Solid compositions
MX2008002512A (es) Composiciones de farmaco que contienen matrices de hipromelosa con liberacion controlada.
NO20070887L (no) Kornformet farmasoytisk preparat med tidsbegrenset frigivelse for oral administrasjon, og intraoral hurtig desintegrerende tablett som inneholder preparatet
MX348361B (es) Formulaciones resistentes al abuso.
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
MX2008012731A (es) Tabletas de paracetamol de liberacion rapida.
MX2010006284A (es) Formulaciones farmaceuticas de fenilefrina y composiciones para la absorcion transmucosal.
PE20142192A1 (es) Forma de dosificacion farmaceutica que comprende nifedipino o nisoldipino y un antagonista de angiotensina ii y/o diuretico
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
WO2007143155A3 (en) Sustained release pharmaceutical dosage form containing phenylephrine
UA116334C2 (uk) Тверді форми дозування бендамустину
WO2006123357A3 (en) Oral controlled release composition containing levetiracetam
WO2010103544A3 (en) A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants
RU2015143515A (ru) Твердые таблетки и капсулы модифицированного высвобождения бензонатата
AU2003270255A1 (en) Fast releasing, solid administration form for oral application of active ingredients which are hard to dissolve
WO2008142572A3 (en) Controlled release tablet formulation containing magnesium aluminometasilicate
TW200624126A (en) New modified release tablet formulations for proton pump inhibitors
MY151468A (en) Controlled release solid preparation
WO2007143163A3 (en) Pharmaceutical compositions for sustained release of phenyephrine
TW200635617A (en) Multiparticulate pharmaceutical form comprising mucoadhesively formulated nucleic acid active ingredients, and a process for producing the pharmaceutical form
MX2010004556A (es) Formulacion farmaceutica de acido clavulanico.
UA106361C2 (ru) Фармацевтическая композиция для лечения эссенциальной тромбоцитемии

Legal Events

Date Code Title Description
FA Abandonment or withdrawal